Literature DB >> 22781681

Antibody specification beyond the target: claiming a later-generation therapeutic antibody by its target epitope.

Colin G Sandercock1, Ulrich Storz.   

Abstract

Mesh:

Substances:

Year:  2012        PMID: 22781681     DOI: 10.1038/nbt.2291

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  3 in total

1.  An update on obtaining and enforcing therapeutic antibody patent claims.

Authors:  Theresa Gresl; Ulrich Storz; Colin Sandercock
Journal:  Nat Biotechnol       Date:  2016-12-07       Impact factor: 54.908

Review 2.  Rituximab: how approval history is reflected by a corresponding patent filing strategy.

Authors:  Ulrich Storz
Journal:  MAbs       Date:  2014-05-19       Impact factor: 5.857

3.  Enhancing antibody patent protection using epitope mapping information.

Authors:  Xiaoxiang Deng; Ulrich Storz; Benjamin J Doranz
Journal:  MAbs       Date:  2017-12-07       Impact factor: 5.857

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.